SCHEMBL13628308

SCHEMBL13628308

CCC(=O)Nc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.39
ALDH1A1 P00352 6/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 5/20 0.37
HPGD P15428 3/20 0.37
POLB P06746 4/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GALR3 O60755 1/20 0.36
NR2F2 P24468 1/20 0.36
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628163 0.94 KDM4E (0.43) MAPK8ALDH1A1TDP1KDM4EHPGD
SCHEMBL13628152 0.92 MAPK8 (0.39) MAPK8ALDH1A1TDP1KDM4EPOLB
SCHEMBL13628164 0.91 MAPK8 (0.38) MAPK8ALDH1A1TDP1POLBRAB9A
SCHEMBL13628206 0.91 TDP1 (0.38) MAPK8ALDH1A1TDP1KDM4EPOLB
SCHEMBL13628309 0.91 LMNA (0.38) MAPK8ALDH1A1TDP1KDM4EPOLB
SCHEMBL13628155 0.91 KDM4E (0.38) MAPK8ALDH1A1TDP1KDM4EPOLB
SCHEMBL13628314 0.91 ALDH1A1 (0.37) MAPK8ALDH1A1TDP1KDM4EPOLB
SCHEMBL13628208 0.90 KDM4E (0.38) MAPK8ALDH1A1TDP1KDM4EHPGD
SCHEMBL13637555 0.90 MAPK8 (0.40) MAPK8ALDH1A1TDP1KDM4EPOLB
SCHEMBL13628312 0.89 ALDH1A1 (0.36) MAPK8ALDH1A1TDP1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 MAPK8 58/4885ALDH1A1 4310/4885TDP1 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.